|  |  | 

India Top Headlines

One in four people experience mild side effects from the Covishield Covid-19 vaccine: Lancet study | India News


NEW DELHI: One in four people experience mild and short-lived systemic side effects after receiving Pfizer’s Covid-19 preventive vaccine or AstraZeneca vaccine, known as Covishield in India, with headache, fatigue and tenderness as symptoms plus common, according to a study published in the Lancet Infectious Diseases.
Researchers at King’s College London in the UK also found that most systemic side effects – that is, side effects that exclude the injection site – peaked within the first 24 hours after injection. vaccination and generally lasted 1 to 2 days.
Analysis of data from the ZOE Covid Symptom Study app found far fewer side effects in the general population with the Pfizer and AstraZeneca vaccines than were reported in the trials.
The study also reports a significant decrease in infection rates 12 to 21 days after the first dose of the Pfizer (58% reduction) and AstraZeneca (39% reduction) vaccines compared to a control group.
The fall in infection at least 21 days after the first dose of Pfizer is 69 percent and AstraZeneca 60 percent, according to the study.
Systemic effects included headache, fatigue, chills and chills, diarrhea, fever, arthralgia, myalgia, and nausea.
Local side effects, that is, side effects where the injection took place in the arm, included pain at the injection site, swelling, tenderness, redness, itching, warmth, and swelling of the axillary glands.
“The data should reassure many people that in the real world, the after-effects of the vaccine are often mild and short-lived, especially in those over 50 who are at higher risk of infection,” said the professor. Tim Spector, Lead Scientist for the ZOE Covid Symptom Study App and Professor at King’s College London.
Data comes from 627,383 ZOE Covid Symptom Study app users who self-reported systemic and local effects within eight days of receiving one or two doses of Pfizer vaccine or one dose of AstraZeneca vaccine between December 8 and On March 10.
The study also found that side effects were more common among people under the age of 55 and among women.
Participants who had a previous confirmed case of Covid-19 were three times more likely to have whole-body side effects after receiving doses of the Pfizer vaccine than those without a known infection.
Those with a previously numbered confirmed case of Covid-19 were nearly twice as likely to have whole-body side effects after the first dose of the AstraZeneca vaccine.
People with a known previous Covid-19 infection were also more likely to experience local side effects, the researchers said.
The researchers noted that in phase III clinical trials of the Pfizer vaccine, the most common side effects were injection site pain (71-83%), fatigue (34-47%), and headache (25- 42%). .
However, real-world analysis found that less than 30 percent of users complained of injection site pain and less than 10 percent of fatigue and headache after the first dose, they said.
Similarly, in phase III trials for the AstraZeneca vaccine, systemic side effects were found in 88 percent of the youngest participants (18-55 years) after the first dose, but the study found a significantly higher rate. 46.2 percent drop after the first dose.
“Our results support the safety of the sequelae of both vaccines with fewer side effects in the general population than was reported in the Pfizer and AstraZeneca experimental trials and should help allay the safety concerns of people wanting to be vaccinated.” Spector added.

Original source